Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novartis announces new Alzheimer’s research collaboration

Novartis announces new Alzheimer’s research collaboration

16th July 2014

Novartis has announced a new collaboration with the Banner Alzheimer's Institute (BAI), which will focus on research into a promising new therapy approach.

The organisations will ally to conduct a pioneering clinical study to determine whether two of Novartis' investigational anti-amyloid treatments can prevent or delay the emergence of symptoms of Alzheimer's among those at risk of developing the late-onset form of the disease.

Both treatments will be given to cognitively healthy people with a genetic risk of developing the build-up of amyloid protein in the brain that may eventually lead to the condition manifesting.

The first of these treatments is an active immunotherapy that triggers the production of natural antibodies against amyloid, while the second is a BACE inhibitor designed to prevent the production of different forms of amyloid.

David Epstein, division head at Novartis Pharmaceuticals, said: "There is a huge unmet need for treatments that prevent or delay the development of the disease and we are excited about taking research in Alzheimer's to the next level."

This comes after the firm recently reported data from two clinical trials demonstrating the strong efficacy of its drug secukinumab in psoriasis patients.ADNFCR-8000103-ID-801735570-ADNFCR

We currently have 10 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.